Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Settings
2.2. Assessment Tools
2.2.1. Psodisk
2.2.2. Hamilton Anxiety Rating Scale (HAM-A)
2.2.3. Hamilton Rating Scale for Depression (HAM-D)
2.2.4. Symptom Checklist-90-Revised (SCL-90-R)
2.2.5. 36-Item Short Form Health Survey (SF-36)
2.3. Statistical Analysis
3. Results
3.1. Sociodemographic Characteristics of the Sample
3.2. Univariate Analyses
3.3. Multivariate Analysis
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Armstrong, A.W.; Mehta, M.D.; Schupp, C.W.; Gondo, G.C.; Bell, S.J.; Griffiths, C.E.M. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021, 157, 940–946. [Google Scholar] [CrossRef] [PubMed]
- Hernandez-Nicols, B.F.; Robledo-Pulido, J.J.; Alvarado-Navarro, A. Etiopathogenesis of Psoriasis: Integration of Proposed Theories. Immunol. Investig. 2024, 53, 348–415. [Google Scholar] [CrossRef] [PubMed]
- Babaie, F.; Omraninava, M.; Gorabi, A.M.; Khosrojerdi, A.; Aslani, S.; Yazdchi, A.; Torkamandi, S.; Mikaeili, H.; Sathyapalan, T.; Sahebkar, A. Etiopathogenesis of Psoriasis from Genetic Perspective: An Updated Review. Curr. Genom. 2022, 23, 163–174. [Google Scholar] [CrossRef]
- Kocaaga, A.; Kocaaga, M. Psoriasis: An Immunogenetic Perspective. Glob. Med. Genet. 2022, 9, 82–89. [Google Scholar] [CrossRef] [PubMed]
- Zhou, X.; Chen, Y.; Cui, L.; Shi, Y.; Guo, C. Advances in the Pathogenesis of Psoriasis: From Keratinocyte Perspective. Cell Death Dis. 2022, 13, 81. [Google Scholar] [CrossRef]
- Goodfield, M. Skin Lesions in Psoriasis. Baillieres Clin. Rheumatol. 1994, 8, 295–316. [Google Scholar] [CrossRef]
- Kimball, A.B.; Gladman, D.; Gelfand, J.M.; Gordon, K.; Horn, E.J.; Korman, N.J.; Korver, G.; Krueger, G.G.; Strober, B.E.; Lebwohl, M.G.; et al. National Psoriasis Foundation Clinical Consensus on Psoriasis Comorbidities and Recommendations for Screening. J. Am. Acad. Dermatol. 2008, 58, 1031–1042. [Google Scholar] [CrossRef]
- Yamazaki, F. Psoriasis: Comorbidities. J. Dermatol. 2021, 48, 732–740. [Google Scholar] [CrossRef]
- Maj, M. Understanding Depression beyond the “Mind-Body” Dichotomy. World Psychiatry 2023, 22, 349–350. [Google Scholar] [CrossRef]
- Hedemann, T.L.; Liu, X.; Kang, C.N.; Husain, M.I. Associations between Psoriasis and Mental Illness: An Update for Clinicians. Gen. Hosp. Psychiatry 2022, 75, 30–37. [Google Scholar] [CrossRef]
- Rabin, F.; Bhuiyan, S.I.; Islam, T.; Haque, M.A.; Islam, M.A. Psychiatric and Psychological Comorbidities in Patients with Psoriasis—A Review. Mymensingh Med. J. 2012, 21, 780–786. [Google Scholar] [PubMed]
- Adesanya, E.I.; Matthewman, J.; Schonmann, Y.; Hayes, J.F.; Henderson, A.; Mathur, R.; Mulick, A.R.; Smith, C.H.; Langan, S.M.; Mansfield, K.E. Factors Associated with Depression, Anxiety and Severe Mental Illness among Adults with Atopic Eczema or Psoriasis: A Systematic Review and Meta-Analysis. Br. J. Dermatol. 2023, 188, 460–470. [Google Scholar] [CrossRef] [PubMed]
- Dowlatshahi, E.A.; Wakkee, M.; Arends, L.R.; Nijsten, T. The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis. J. Investig. Dermatol. 2014, 134, 1542–1551. [Google Scholar] [CrossRef]
- Pompili, M.; Bonanni, L.; Gualtieri, F.; Trovini, G.; Persechino, S.; Baldessarini, R.J. Suicidal Risks with Psoriasis and Atopic Dermatitis: Systematic Review and Meta-Analysis. J. Psychosom. Res. 2021, 141, 110347. [Google Scholar] [CrossRef]
- Kurd, S.K.; Troxel, A.B.; Crits-Christoph, P.; Gelfand, J.M. The Risk of Depression, Anxiety, and Suicidality in Patients with Psoriasis: A Population-Based Cohort Study. Arch Dermatol. 2010, 146, 891–895. [Google Scholar] [CrossRef] [PubMed]
- Singhal, A.; Ross, J.; Seminog, O.; Hawton, K.; Goldacre, M.J. Risk of Self-Harm and Suicide in People with Specific Psychiatric and Physical Disorders: Comparisons between Disorders Using English National Record Linkage. J. R. Soc. Med. 2014, 107, 194–204. [Google Scholar] [CrossRef]
- Hickie, I.B.; Crouse, J.J. Sleep and Circadian Rhythm Disturbances: Plausible Pathways to Major Mental Disorders? World Psychiatry 2024, 23, 150–151. [Google Scholar] [CrossRef]
- Rieder, E.; Tausk, F. Psoriasis, a Model of Dermatologic Psychosomatic Disease: Psychiatric Implications and Treatments. Int. J. Dermatol. 2012, 51, 12–26. [Google Scholar] [CrossRef] [PubMed]
- Gupta, M.A.; Simpson, F.C.; Gupta, A.K. Psoriasis and Sleep Disorders: A Systematic Review. Sleep Med. Rev. 2016, 29, 63–75. [Google Scholar] [CrossRef]
- Shutty, B.G.; West, C.; Huang, K.E.; Landis, E.; Dabade, T.; Browder, B.; O’Neill, J.; Kinney, M.A.; Feneran, A.N.; Taylor, S.; et al. Sleep Disturbances in Psoriasis. Dermatol. Online J. 2013, 19, 1. [Google Scholar] [CrossRef]
- Wan, M.T.; Pearl, R.L.; Chiesa Fuxench, Z.C.; Takeshita, J.; Gelfand, J.M. Anticipated and Perceived Stigma Among Patients with Psoriasis. J. Psoriasis Psoriatic Arthritis 2020, 5, 93–99. [Google Scholar] [CrossRef] [PubMed]
- Grover, S.; Mehra, A.; Dogra, S.; Hazari, N.; Malhora, N.; Narang, T.; Sahoo, S.; Sharma, S.; Handa, S.; Avasthi, A. Internalized Stigma and Psychiatric Morbidity among Patients with Psoriasis: A Study from North India. Indian Dermatol. Online J. 2021, 12, 97–104. [Google Scholar] [CrossRef] [PubMed]
- Kimball, A.B.; Jacobson, C.; Weiss, S.; Vreeland, M.G.; Wu, Y. The Psychosocial Burden of Psoriasis. Am. J. Clin. Dermatol. 2005, 6, 383–392. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, A.W.; Bohannan, B.; Mburu, S.; Coates, L.C.; Ogdie, A.; Alarcon, I.; Kasparek, T.; Frade, S.; Barrio, S.F.; Augustin, M. Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey. Dermatology 2023, 239, 621–634. [Google Scholar] [CrossRef]
- Berk, M.; Köhler-Forsberg, O.; Turner, M.; Penninx, B.W.J.H.; Wrobel, A.; Firth, J.; Loughman, A.; Reavley, N.J.; McGrath, J.J.; Momen, N.C.; et al. Comorbidity between Major Depressive Disorder and Physical Diseases: A Comprehensive Review of Epidemiology, Mechanisms and Management. World Psychiatry 2023, 22, 366–387. [Google Scholar] [CrossRef]
- Hrehorów, E.; Salomon, J.; Matusiak, L.; Reich, A.; Szepietowski, J.C. Patients with Psoriasis Feel Stigmatized. Acta Derm. Venereol. 2012, 92, 67–72. [Google Scholar] [CrossRef]
- Fiorillo, A.; de Girolamo, G.; Simunovic, I.F.; Gureje, O.; Isaac, M.; Lloyd, C.; Mari, J.; Patel, V.; Reif, A.; Starostina, E.; et al. The Relationship between Physical and Mental Health: An Update from the WPA Working Group on Managing Comorbidity of Mental and Physical Health. World Psychiatry 2023, 22, 169–170. [Google Scholar] [CrossRef] [PubMed]
- Dragioti, E.; Radua, J.; Solmi, M.; Gosling, C.J.; Oliver, D.; Lascialfari, F.; Ahmed, M.; Cortese, S.; Estradé, A.; Arrondo, G.; et al. Impact of Mental Disorders on Clinical Outcomes of Physical Diseases: An Umbrella Review Assessing Population Attributable Fraction and Generalized Impact Fraction. World Psychiatry 2023, 22, 86–104. [Google Scholar] [CrossRef]
- Fabrazzo, M.; Cipolla, S.; Signoriello, S.; Camerlengo, A.; Calabrese, G.; Giordano, G.M.; Argenziano, G.; Galderisi, S. A Systematic Review on Shared Biological Mechanisms of Depression and Anxiety in Comorbidity with Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa. Eur. Psychiatry 2021, 64, e71. [Google Scholar] [CrossRef]
- Blackstone, B.; Patel, R.; Bewley, A. Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician. Psoriasis 2022, 12, 25–33. [Google Scholar] [CrossRef]
- Griffiths, C.E.; Richards, H.L. Psychological Influences in Psoriasis. Clin. Exp. Dermatol. 2001, 26, 338–342. [Google Scholar] [CrossRef] [PubMed]
- Krantz, Å.; Carrero, J.J.; Yang, Y.; Schalin, L.; Lysell, J.; Mazhar, F. Psoriasis/Psoriatic Arthritis Patients’ Long-Term Treatment Patterns and Adherence to Systemic Treatments Monitoring Recommendations. Acta Derm. Venereol. 2023, 103, adv6505. [Google Scholar] [CrossRef] [PubMed]
- Dalgard, F.J.; Gieler, U.; Tomas-Aragones, L.; Lien, L.; Poot, F.; Jemec, G.B.E.; Misery, L.; Szabo, C.; Linder, D.; Sampogna, F.; et al. The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological out-Patients in 13 European Countries. J. Investig. Dermatol. 2015, 135, 984–991. [Google Scholar] [CrossRef]
- O’Leary, C.J.; Creamer, D.; Higgins, E.; Weinman, J. Perceived Stress, Stress Attributions and Psychological Distress in Psoriasis. J. Psychosom. Res. 2004, 57, 465–471. [Google Scholar] [CrossRef]
- Langley, R.G.B.; Krueger, G.G.; Griffiths, C.E.M. Psoriasis: Epidemiology, Clinical Features, and Quality of Life. Ann. Rheum. Dis. 2005, 64 (Suppl. 2), ii18-23; discussion ii24-25. [Google Scholar] [CrossRef]
- Boswell, N.D.; Cook, M.K.; Balogh, E.A.; Feldman, S.R. The Impact of Complete Clearance and Almost Complete Clearance of Psoriasis on Quality of Life: A Literature Review. Arch Dermatol. Res. 2023, 315, 699–706. [Google Scholar] [CrossRef]
- Heller, M.M.; Wong, J.W.; Nguyen, T.V.; Lee, E.S.; Bhutani, T.; Menter, A.; Koo, J.Y.M. Quality-of-Life Instruments: Evaluation of the Impact of Psoriasis on Patients. Dermatol. Clin. 2012, 30, 281–291, ix. [Google Scholar] [CrossRef]
- Parrish, L. Psoriasis: Symptoms, Treatments and Its Impact on Quality of Life. Br. J. Community Nurs. 2012, 17, 524, 526, 528. [Google Scholar] [CrossRef] [PubMed]
- Feldman, S.R. Psoriasis Causes as Much Disability as Other Major Medical Diseases. J. Am. Acad. Dermatol. 2020, 82, 256–257. [Google Scholar] [CrossRef]
- Iannone, M.; Janowska, A.; Panduri, S.; Morganti, R.; Davini, G.; Romanelli, M.; Dini, V. Impact of Psychiatric Comorbidities in Psoriasis, Hidradenitis Suppurativa and Atopic Dermatitis: The Importance of a Psychodermatological Approach. Exp. Dermatol. 2022, 31, 956–961. [Google Scholar] [CrossRef]
- Brandt, V.; Zhang, Y.; Carr, H.; Golm, D.; Correll, C.U.; Arrondo, G.; Firth, J.; Hassan, L.; Solmi, M.; Cortese, S. First Evidence of a General Disease (“d”) Factor, a Common Factor Underlying Physical and Mental Illness. World Psychiatry 2023, 22, 335–337. [Google Scholar] [CrossRef] [PubMed]
- Alegria, M. The Need to Bring Community, Policy Makers and Researchers to the Table in Prevention Programs. World Psychiatry 2024, 23, 94–95. [Google Scholar] [CrossRef] [PubMed]
- Mattei, P.L.; Corey, K.C.; Kimball, A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The Correlation between Disease Severity and Psychological Burden in Patients Treated with Biological Therapies. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 333–337. [Google Scholar] [CrossRef]
- Reich, K.; Daudén, E. Treatment Adherence: A Hurdle for Real-Life Effectiveness in Psoriasis? J. Eur. Acad. Dermatol. Venereol. 2014, 28 (Suppl. 2), 1–3. [Google Scholar] [CrossRef] [PubMed]
- Yélamos, O.; Ros, S.; Puig, L. Improving Patient Outcomes in Psoriasis: Strategies to Ensure Treatment Adherence. Psoriasis 2015, 5, 109–115. [Google Scholar] [CrossRef]
- Overview|Psoriasis: Assessment and Management|Guidance|NICE. Available online: https://www.nice.org.uk/guidance/cg153 (accessed on 23 August 2024).
- Linder, D.; Sampogna, F.; Torreggiani, A.; Balato, N.; Bianchi, L.; Cassano, N.; Conti, A.; Gisondi, P.; Musumeci, M.L.; Piaserico, S.; et al. Psodisk, a New Visual Method for Assessing the Burden of Psoriasis on Patients. J. Eur. Acad. Dermatol. Venereol. 2012, 26, 1163–1166. [Google Scholar] [CrossRef]
- Sampogna, F.; Linder, D.; Romano, G.V.; Gualberti, G.; Merolla, R.; di Luzio Paparatti, U. Results of the Validation Study of the Psodisk Instrument, and Determination of the Cut-off Scores for Varying Degrees of Impairment. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 725–731. [Google Scholar] [CrossRef] [PubMed]
- Hamilton, M. The Assessment of Anxiety States by Rating. Br. J. Med. Psychol. 1959, 32, 50–55. [Google Scholar] [CrossRef]
- Leentjens, A.F.G.; Dujardin, K.; Marsh, L.; Richard, I.H.; Starkstein, S.E.; Martinez-Martin, P. Anxiety Rating Scales in Parkinson’s Disease: A Validation Study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale. Mov. Disord. 2011, 26, 407–415. [Google Scholar] [CrossRef]
- Hamilton, M. A Rating Scale for Depression. J. Neurol. Neurosurg. Psychiatry 1960, 23, 56–62. [Google Scholar] [CrossRef]
- Mula, M.; Iudice, A.; La Neve, A.; Mazza, M.; Mazza, S.; Cantello, R.; Kanner, A.M. Validation of the Hamilton Rating Scale for Depression in Adults with Epilepsy. Epilepsy Behav. 2014, 41, 122–125. [Google Scholar] [CrossRef] [PubMed]
- Derogatis, L.R.; Lipman, R.S.; Covi, L. SCL-90: An Outpatient Psychiatric Rating Scale—Preliminary Report. Psychopharmacol. Bull 1973, 9, 13–28. [Google Scholar]
- Zimmerman, M. The Value and Limitations of Self-Administered Questionnaires in Clinical Practice and Epidemiological Studies. World Psychiatry 2024, 23, 210–212. [Google Scholar] [CrossRef] [PubMed]
- Prunas, A.; Sarno, I.; Preti, E.; Madeddu, F.; Perugini, M. Psychometric Properties of the Italian Version of the SCL-90-R: A Study on a Large Community Sample. Eur. Psychiatr. 2012, 27, 591–597. [Google Scholar] [CrossRef]
- Ware, J.E.; Sherbourne, C.D. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual Framework and Item Selection. Med. Care 1992, 30, 473–483. [Google Scholar] [CrossRef]
- Apolone, G.; Mosconi, P. The Italian SF-36 Health Survey: Translation, Validation and Norming. J. Clin. Epidemiol. 1998, 51, 1025–1036. [Google Scholar] [CrossRef] [PubMed]
- Rimm, E.; Ellison, R. Alcohol in the Mediterranean Diet. Am. J. Clin. Nutr. 1995, 61, 1378S–1382S. [Google Scholar] [CrossRef] [PubMed]
- Gureje, O. Deconstructing the Social Determinants of Mental Health. World Psychiatry 2024, 23, 99–100. [Google Scholar] [CrossRef]
- Haslam, N. Dehumanization and Mental Health. World Psychiatry 2024, 23, 173–174. [Google Scholar] [CrossRef]
- Parisi, R.; Iskandar, I.Y.K.; Kontopantelis, E.; Augustin, M.; Griffiths, C.E.M.; Ashcroft, D.M. Global Psoriasis Atlas National, Regional, and Worldwide Epidemiology of Psoriasis: Systematic Analysis and Modelling Study. BMJ 2020, 369, m1590. [Google Scholar] [CrossRef]
- Sampogna, G.; Luciano, M.; Di Vincenzo, M.; Andriola, I.; D’Ambrosio, E.; Amore, M.; Serafini, G.; Rossi, A.; Carmassi, C.; Dell’Osso, L.; et al. The Complex Interplay between Physical Activity and Recovery Styles in Patients with Severe Mental Disorders in a Real-World Multicentric Study. Front. Psychiatry 2022, 13, 945650. [Google Scholar] [CrossRef]
- Luciano, M.; Sampogna, G.; Del Vecchio, V.; Giallonardo, V.; Palummo, C.; Andriola, I.; Amore, M.; Rossi, R.; Carmassi, C.; Siracusano, A.; et al. The Impact of Clinical and Social Factors on the Physical Health of People with Severe Mental Illness: Results from an Italian Multicentre Study. Psychiatry Res. 2021, 303, 114073. [Google Scholar] [CrossRef]
- Zender, R.; Olshansky, E. Women’s Mental Health: Depression and Anxiety. Nurs. Clin. N. Am. 2009, 44, 355–364. [Google Scholar] [CrossRef] [PubMed]
- Farhane-Medina, N.Z.; Luque, B.; Tabernero, C.; Castillo-Mayén, R. Factors Associated with Gender and Sex Differences in Anxiety Prevalence and Comorbidity: A Systematic Review. Sci. Prog. 2022, 105, 368504221135469. [Google Scholar] [CrossRef]
- Cohen, B.E.; Edmondson, D.; Kronish, I.M. State of the Art Review: Depression, Stress, Anxiety, and Cardiovascular Disease. Am. J. Hypertens. 2015, 28, 1295–1302. [Google Scholar] [CrossRef] [PubMed]
- Sommer, I.E.; Brand, B.A.; Stuijt, C.C.M.; Touw, D.J. Sex Differences Need to Be Considered When Treating Women with Psychotropic Drugs. World Psychiatry 2024, 23, 151–152. [Google Scholar] [CrossRef]
- Martins, A.M.; Ascenso, A.; Ribeiro, H.M.; Marto, J. The Brain-Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System. Cells 2020, 9, 796. [Google Scholar] [CrossRef]
- Lada, G.; Talbot, P.S.; Chinoy, H.; Warren, R.B.; McFarquhar, M.; Kleyn, C.E. Brain Structure and Connectivity in Psoriasis and Associations with Depression and Inflammation; Findings from the UK Biobank. Brain Behav. Immun. Health 2022, 26, 100565. [Google Scholar] [CrossRef] [PubMed]
- Dantzer, R.; O’Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From Inflammation to Sickness and Depression: When the Immune System Subjugates the Brain. Nat. Rev. Neurosci. 2008, 9, 46–56. [Google Scholar] [CrossRef] [PubMed]
- Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A Meta-Analysis of Cytokines in Major Depression. Biol. Psychiatry 2010, 67, 446–457. [Google Scholar] [CrossRef]
- Gisondi, P.; Geat, D.; Bellinato, F.; Spiazzi, L.; Danese, E.; Montagnana, M.; Lippi, G.; Girolomoni, G. Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis. J. Pers. Med. 2021, 11, 1069. [Google Scholar] [CrossRef] [PubMed]
- Gleeson, M.; Bishop, N.C.; Stensel, D.J.; Lindley, M.R.; Mastana, S.S.; Nimmo, M.A. The Anti-Inflammatory Effects of Exercise: Mechanisms and Implications for the Prevention and Treatment of Disease. Nat. Rev. Immunol. 2011, 11, 607–615. [Google Scholar] [CrossRef]
- Reid, C.; Griffiths, C.E.M. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm. Venereol. 2020, 100, adv00032. [Google Scholar] [CrossRef]
- Singh, S.; Young, P.; Armstrong, A.W. An Update on Psoriasis and Metabolic Syndrome: A Meta-Analysis of Observational Studies. PLoS ONE 2017, 12, e0181039. [Google Scholar] [CrossRef]
- Fortune, D.G.; Richards, H.L.; Kirby, B.; McElhone, K.; Main, C.J.; Griffiths, C.E.M. Successful Treatment of Psoriasis Improves Psoriasis-Specific but Not More General Aspects of Patients’ Well-Being. Br. J. Dermatol. 2004, 151, 1219–1226. [Google Scholar] [CrossRef]
- Halioua, B.; Chelli, C.; Misery, L.; Taieb, J.; Taieb, C. Sleep Disorders and Psoriasis: An Update. Acta Derm. Venereol. 2022, 102, adv00699. [Google Scholar] [CrossRef] [PubMed]
- Sahin, E.; Hawro, M.; Weller, K.; Sabat, R.; Philipp, S.; Kokolakis, G.; Christou, D.; Metz, M.; Maurer, M.; Hawro, T. Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 688–697. [Google Scholar] [CrossRef]
- Guo, M.; Su, J.; Zheng, S.; Chen, B. Sleep in Psoriasis: A Meta-Analysis. J. Psychosom. Res. 2024, 176, 111543. [Google Scholar] [CrossRef]
- Irwin, M.R. Why Sleep Is Important for Health: A Psychoneuroimmunology Perspective. Annu. Rev. Psychol. 2015, 66, 143–172. [Google Scholar] [CrossRef] [PubMed]
- Rogers, N.L.; Szuba, M.P.; Staab, J.P.; Evans, D.L.; Dinges, D.F. Neuroimmunologic Aspects of Sleep and Sleep Loss. Semin Clin. Neuropsychiatry 2001, 6, 295–307. [Google Scholar] [CrossRef]
- Trauer, J.M.; Qian, M.Y.; Doyle, J.S.; Rajaratnam, S.M.W.; Cunnington, D. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-Analysis. Ann. Intern Med. 2015, 163, 191–204. [Google Scholar] [CrossRef]
- Chan, N.Y.; Chan, J.W.Y.; Li, S.X.; Wing, Y.K. Non-Pharmacological Approaches for Management of Insomnia. Neurotherapeutics 2021, 18, 32–43. [Google Scholar] [CrossRef]
- Cuijpers, P.; Miguel, C.; Ciharova, M.; Harrer, M.; Basic, D.; Cristea, I.A.; de Ponti, N.; Driessen, E.; Hamblen, J.; Larsen, S.E.; et al. Absolute and Relative Outcomes of Psychotherapies for Eight Mental Disorders: A Systematic Review and Meta-Analysis. World Psychiatry 2024, 23, 267–275. [Google Scholar] [CrossRef]
- Grossman, P.; Niemann, L.; Schmidt, S.; Walach, H. Mindfulness-Based Stress Reduction and Health Benefits. A Meta-Analysis. J. Psychosom. Res. 2004, 57, 35–43. [Google Scholar] [CrossRef]
- Ito, Y.; Browne, C.A.; Yamamoto, K. The Impacts of Mindfulness-Based Stress Reduction (MBSR) on Mindfulness and Well-Being for Regular and Novice Meditators. Mindfulness 2022, 13, 1458–1468. [Google Scholar] [CrossRef]
- Denys, D. Professionals in Psychiatry Need Reflective Competence. World Psychiatry 2024, 23, 234–235. [Google Scholar] [CrossRef]
- Fisher, H.L. The Public Mental Health Revolution Must Privilege Lived Experience Voices and Create Alliances with Affected Communities. World Psychiatry 2024, 23, 2–3. [Google Scholar] [CrossRef]
- O’Donoghue, B. Some Priorities in Targeting Social Determinants to Achieve Prevention of Mental Disorders. World Psychiatry 2024, 23, 98–99. [Google Scholar] [CrossRef]
- Reed, G.M. What’s in a Name? Mental Disorders, Mental Health Conditions and Psychosocial Disability. World Psychiatry 2024, 23, 209–210. [Google Scholar] [CrossRef]
- Slade, M.; Rennick-Egglestone, S.; Elliott, R.A.; Newby, C.; Robinson, C.; Gavan, S.P.; Paterson, L.; Ali, Y.; Yeo, C.; Glover, T.; et al. Effectiveness and Cost-effectiveness of Online Recorded Recovery Narratives in Improving Quality of Life for People with Non-psychotic Mental Health Problems: A Pragmatic Randomized Controlled Trial. World Psychiatry 2024, 23, 101–112. [Google Scholar] [CrossRef]
- van Ommeren, M.; Lewis, S.; Van’t Hof, E.; Carswell, K. Putting Psychological Interventions First in Primary Health Care. World Psychiatry 2023, 22, 390–391. [Google Scholar] [CrossRef]
- Luciano, M.; Sampogna, G.; D’Ambrosio, E.; Rampino, A.; Amore, M.; Calcagno, P.; Rossi, A.; Rossi, R.; Carmassi, C.; Dell’Osso, L.; et al. One-Year Efficacy of a Lifestyle Behavioural Intervention on Physical and Mental Health in People with Severe Mental Disorders: Results from a Randomized Controlled Trial. Eur. Arch. Psychiatry Clin. Neurosci. 2024, 274, 903–915. [Google Scholar] [CrossRef]
- Pearce, M.; Garcia, L.; Abbas, A.; Strain, T.; Schuch, F.B.; Golubic, R.; Kelly, P.; Khan, S.; Utukuri, M.; Laird, Y.; et al. Association between Physical Activity and Risk of Depression: A Systematic Review and Meta-Analysis. JAMA Psychiatry 2022, 79, 550–559. [Google Scholar] [CrossRef]
- Wasserman, D. Mental Health for All: Fostering Healthy Lifestyles. World Psychiatry 2023, 22, 343–344. [Google Scholar] [CrossRef]
- Wasserman, D.; Arango, C.; Fiorillo, A.; Levin, S.; Peters, A.; Rao, P.; Sanchez-Villanueva, T.; Sylla, A. Improving Mental Health through Fostering Healthy Lifestyles in Young People: One of the Targets in the WPA Action Plan 2023–2026. World Psychiatry 2023, 22, 488–489. [Google Scholar] [CrossRef] [PubMed]
- Roster, K.; Kann, R.; Brownstone, N. Prescription Trends of Antidepressant, Anxiolytic, and Anticonvulsant Medications among Dermatologists from 2013 to 2020. Dermatol. Online J. 2023, 29. [Google Scholar] [CrossRef]
- Lewer, D.; O’Reilly, C.; Mojtabai, R.; Evans-Lacko, S. Antidepressant Use in 27 European Countries: Associations with Sociodemographic, Cultural and Economic Factors. Br. J. Psychiatry 2015, 207, 221–226. [Google Scholar] [CrossRef]
- Gomez-Lumbreras, A.; Ferrer, P.; Ballarín, E.; Sabaté, M.; Vidal, X.; Andretta, M.; Coma, A.; Ibáñez, L. Study of Antidepressant Use in 5 European Settings. Could Economic, Sociodemographic and Cultural Determinants Be Related to Their Use? J. Affect Disord. 2019, 249, 278–285. [Google Scholar] [CrossRef]
n | % | |
---|---|---|
Gender | ||
Male | 67 | 59.8 |
Female | 45 | 40.2 |
Age (years) | 48.91 | ±12.73 |
Education | ||
Elementary school | 26 | 23.2 |
Middle school | 46 | 41.1 |
High school | 32 | 28.6 |
University | 8 | 7.1 |
Marital status | ||
With partner | 87 | 77.7 |
Without partner | 25 | 22.3 |
Employed, yes | 56 | 50 |
n | % | |
---|---|---|
BMI | 29.33 | ±6.45 |
Sedentary lifestyle, yes | 89 | 79.5 |
Smoker, yes | 61 | 54.5 |
Alcohol consumption | 109 | 97.3 |
Family history of psychiatric disorders, yes | ||
Positive | 16 | 14.3 |
Personal history of psychiatric disorders | ||
Positive | 9 | 8 |
Ongoing psychiatric drugs administration | ||
Anxiolytic | 12 | 10.7 |
Antidepressant | 9 | 8 |
HAM-A total score | 12.59 | ±9.56 |
HAM-D total score | 11.93 | ±7.67 |
GSI | 60.79 | ±53.63 |
DoPI (years) | 17.4 | ±12.49 |
Arthritis | 31 | 27.7 |
Psodisk total score | 52.24 | ±26.22 |
SF-36 | SCL-90 | ||||
---|---|---|---|---|---|
HAM-A | HAM-D | PCS | MCS | GSI | |
Age | 0.108 | 0.005 | −0.242 * | −0.204 * | 0.032 |
BMI | 0.182 | 0.081 | −0.222 * | −0.225 * | 0.099 |
DoPI | −0.089 | −0.086 | −0.022 | 0.094 | −0.048 |
Psodisk | |||||
Health | 0.500 *** | 0.462 *** | −0.523 *** | −0.464 *** | 0.493 *** |
Pain | 0.525 *** | 0.415 *** | −0.563 *** | −0.443 *** | 0.442 *** |
Itch | 0.321 *** | 0.313 *** | −0.278 ** | −0.389 *** | 0.359 *** |
Sleep | 0.456 *** | 0.409 *** | −0.435 *** | −0.488 *** | 0.467 *** |
Social life | 0.331 *** | 0.220 * | −0.228 * | −0.324 *** | 0.383 *** |
Work and other daily activities | 0.265 *** | 0.132 | −0.345 *** | −0.349 *** | 0.246 ** |
Peace of mind | 0.399 *** | 0.333 *** | −0.390 *** | −0.520 *** | 0.405 *** |
Sexual life | 0.241 * | 0.197 * | −0.245 ** | −0.320 *** | 0.356 *** |
Shame | 0.331 *** | 0.289 *** | −0.237 * | −0.346 *** | 0.407 *** |
Skin involvement | 0.288 *** | 0.315 *** | −0.224 * | −0.290 ** | 0.341 *** |
SF-36 | SCL-90 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
HAM-A B (95% IC) | HAM-D B (95% IC) | PCS B (95% IC) | MCS B (95% IC) | GSI B (95% IC) | ||||||
Adjusted R2 | 0.440 | 0.300 | 0.382 | 0.390 | 0.310 | |||||
Age | 0.05 | (−0.07/0.17) | −0.06 | (−0.17/0.05) | −0.20 | (−0.52/0.12) | −0.26 | (−0.56/0.03) | −0.27 | (−1.03/0.49) |
Gender (male) | −3.92 * | (−7.35/−0.49) | −3.42 * | (−6.52/−0.32) | 2.31 | (−6.65/11.27) | 7.69 | (−0.65/16.02) | −14.44 | (−35.87/6.98) |
BMI | 0.13 | (−0.10/0.36) | −0.02 | (−0.23/0.18) | −0.60 | (−1.19/0.00) | −0.46 | (−1.02/0.09) | 0.10 | (−1.33/1.53) |
Physical activity (sedentary lifestyle) | 2.71 | (−1.07/6.49) | 4.02 * | (0.60/7.43) | −6.34 | (−16.21/3.53) | −2.48 | (−11.66/6.70) | 8.99 | (−14.61/32.58) |
Personal history of psychiatric disorders (negative) | −4.84 | (−10.33/0.65) | −1.47 | (−6.43/3.49) | −0.91 | (−15.25/13.43) | 4.50 | (−8.83/17.83) | −20.07 | (−54.35/14.21) |
DoPI | −0.14 * | (−0.27/−0.02) | −0.09 | (−0.20/0.03) | 0.11 | (−0.22/0.43) | 0.27 | (−0.03/0.57) | −0.37 | (−1.14/0.41) |
Arthritis (absent) | −2.22 | (−6.07/1.62) | −0.12 | (−3.60/3.35) | 2.60 | (−7.45/12.65) | −0.22 | (−9.57/9.13) | −4.18 | (−28.21/19.85) |
Psodisk | ||||||||||
Health | 0.24 | (−0.47/0.96) | 0.51 | (−0.13/1.16) | −1.10 | (−2.96/0.76) | −0.47 | (−2.19/1.26) | 3.10 | (−1.34/7.53) |
Pain | 0.62 * | (0.05 7/1.19) | 0.28 | (−0.24/0.79) | −2.03 ** | (−3.52/−0.54) | −0.46 | (−1.85/0.93) | 1.52 | (−2.05/5.09) |
Itch | −0.39 | (−0.98/0.19) | −0.18 | (−0.71/0.34) | 0.49 | (−1.04/2.02) | 0.21 | (−1.21/1.63) | −0.78 | (−4.43/2.88) |
Sleep | 0.68 ** | (0.20/1.17) | 0.60 ** | (0.16/1.04) | −1.46 ** | (−2.73/−0.19) | −1.57 * | (−2.75/−0.39) | 3.91 * | (0.87/6.95) |
Social life | 0.21 | (−0.40/0.82) | 0.13 | (−0.42/0.68) | 0.14 | (−1.45/1.73) | 0.15 | (−1.33/1.63) | 0.91 | (−2.89/4.72) |
Work and other daily activities | −0.29 | (−0.82/0.23) | −0.31 | (−0.78/0.16) | −0.10 | (−1.46/1.26) | −0.31 | (−1.58/0.95) | −1.63 | (−4.89/1.63) |
Peace of mind | 0.54 | (−0.12/1.20) | 0.15 | (−0.45/0.75) | −1.07 | (−2.80/0.66) | −2.30 ** | (−3.91/−0.69) | 0.91 | (−3.22/5.05) |
Sexual life | −0.15 | (−0.77/0.48) | −0.30 | (−0.86/0.27) | −0.22 | (−1.85/1.41) | −0.05 | (−1.57/1.46) | 1.23 | (−2.67/5.14) |
Shame | 0.13 | (−0.47/0.72) | 0.12 | (−0.42/0.66) | 0.12 | (−1.43/1.67) | 0.10 | (−1.34/1.54) | 1.56 | (−2.15/5.26) |
Skin involvement | −0.02 | (−0.75/0.72) | 0.04 | (−0.63/0.71) | 1.33 | (−0.59/3.26) | 0.89 | (−0.90/2.68) | −0.22 | (−4.83/4.38) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cipolla, S.; Catapano, P.; Bonamico, A.F.; De Santis, V.; Murolo, R.; Romano, F.; Volpicelli, A.; Perris, F.; Lo Schiavo, A.; Fabrazzo, M.; et al. Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study. Brain Sci. 2024, 14, 865. https://doi.org/10.3390/brainsci14090865
Cipolla S, Catapano P, Bonamico AF, De Santis V, Murolo R, Romano F, Volpicelli A, Perris F, Lo Schiavo A, Fabrazzo M, et al. Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study. Brain Sciences. 2024; 14(9):865. https://doi.org/10.3390/brainsci14090865
Chicago/Turabian StyleCipolla, Salvatore, Pierluigi Catapano, Antonio Fiorino Bonamico, Valeria De Santis, Roberta Murolo, Francesca Romano, Antonio Volpicelli, Francesco Perris, Ada Lo Schiavo, Michele Fabrazzo, and et al. 2024. "Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study" Brain Sciences 14, no. 9: 865. https://doi.org/10.3390/brainsci14090865